Updates are available Correction dated 2024-06-18
Click to view Correction: https://doi.org/10.1038/s41591-024-03137-w
Updates are available Correction dated 2024-07-02
Click to view Correction: https://doi.org/10.1038/s41591-024-03157-6
-
Authors
Li, Roger http://orcid.org/0000-0003-1274-7200
Shah, Paras H.
Stewart, Tyler F.
Nam, Jong Kil
Bivalacqua, Trinity J.
Lamm, Donald L.
Uchio, Edward M.
Geynisman, Daniel M.
Jacob, Joseph M.
Meeks, Joshua J. http://orcid.org/0000-0002-5444-5510
Dickstein, Rian
Pearce, Shane M.
Kang, Seok Ho
Jung, Seung Il
Kamat, Ashish M. http://orcid.org/0000-0003-3546-9928
Burke, James M.
Keegan, Kirk A.
Steinberg, Gary D.
- License Information
-
More Information
Article History
Received: 5 April 2024
Accepted: 29 April 2024
First Online: 6 June 2024
Change Date: 18 June 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-024-03137-w
Change Date: 2 July 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-024-03157-6
Competing interests
: R.L.: research support: Predicine; Veracyte; CG Oncology; Valar labs; scientific advisor/consultant: BMS, Merck, CG Oncology, Iconovir; speaker bureau: Predicine; travel: Predicine, CG Oncology. T.S.: research support: GRAIL; scientific advisor/consultant: Astellas, AstraZeneca, Pfizer, Seagen. E.M.U.: clinical trials: CG Oncology, Pfizer, Janssen, Merck, enGene; consultant: Pfizer, Janssen, Merck. D.M.G.: research support to institution: Genentech, Merck, Arvinas, Astellas, Harpoon Therapeutics; scientific advisor/consultant: Pfizer, Exelixis, AstraZeneca, Seattle Genetics/Astellas, Merck, BMS. J.M.J.: consulting: Pfizer, Janssen. J.J.M.: consultant: Merck, AstraZeneca, Incyte, Janssen, BMS, UroGen, Prokarium, Imvax, Pfizer, Seagen/Astellas, Ferring; research funding: VHA, NIH, DoD; compensation for talks/educational courses: AUA, OncLive, Olympus, UroToday; Clinical Trials: SWOG, Genentech, Merck, AstraZeneca; two patents: T1 and TCGA classifier. R.D.: consulting: CG Oncology, CIVCO, Ferring, ImmunityBio, Johnson & Johnson, Olympus; speaker: BMS, Uorgen. A.M.K.: grants: FKD Therapies (Ferring), PCORI, Photocure, Seagen, EnGene, Arquer Diagnostics, SWOG; consulting: Astellas Pharma, Biological Dynamics, BMS, CG Oncology, Cystotech, Eisai, EnGene, Ferring, Imagin Medical, Imvax, Incyte, Janssen, Medac, Merck, Nonagen Bioscience, Pfizer, Protara Therapeutics, Roche, Seagen, Sessen Bio, Theralase, Urogen Pharma, US Biotest, Vivet Therapeutics; patent: CyPRIT. J.M.B.: CG Oncology consultant, former CMO, stock/options; Kalivir CMO, stock options; Affyimmune consultant. K.A.K.: employee of CG Oncology, stock/options. G.D.S.: clinical trial committee: Merck, BMS, Janssen, CG Oncology, Pfizer, Fidia, Seagen, Protara, EnGene Bio; consulting: CG Oncology, PhotoCure, Merck, Taris Biomedical (Now Janssen), Fidia Farmaceuticals, Urogen, Ferring, BMS, AstraZeneca, Pfizer, Janssen, Epivax Therapeutics, EnGene Bio, Astellas, SeaGen, Verity Pharmaceuticals, Protara, xCures, Nonagen, Nanology, Imvax, Asieris, UroViu, Aura Biosciences, Nucleix, Vesica Health; stock/options: Epivax Therapeutics, CG Oncology, EnGene Bio, Vesica. All other authors declare no competing interests.
